EPRX Overview

Clinical Trial Results: Cohorts 5 and 6 of the RESOLVE trial show that 4 out of 6 patients remain in clinical remission 52 weeks after a single administration of EP-104GI for eosinophilic esophagitis (EoE), with no serious adverse events reported.

Durability and Tolerability: The data indicates a durable clinical symptom response, with 67% of patients in clinical remission at week 36 and significant reductions in dysphagia symptoms measured by the Straumann Dysphagia Index.

Innovative Treatment Approach: EP-104GI, administered via esophageal wall injections, represents a novel treatment strategy for EoE, potentially offering a once-a-year treatment option that aligns with routine patient endoscopies.

Future Developments: Eupraxia Pharmaceuticals plans to disclose additional data from the RESOLVE trial and is currently recruiting for the Phase 2b part of the trial, with top-line data expected in Q3 2026.

Canada Growth Conference: The third Canada Growth Conference is taking place in Dublin, hosted by Peterson Capital, featuring seven of Canada's fastest-growing public companies and over fifty industry professionals.

Event Highlights: Attendees will engage in presentations, networking, and a unique 'Bear Pit' session with CEOs, culminating in a vote for the top growth story, with the winner receiving the Canada Growth Cup.

Successful Public Offering: Eupraxia Pharmaceuticals closed a public offering of 14,636,363 common shares at $5.50 each, raising approximately $80.5 million to support the development of its drug EP-104GI and other clinical initiatives.

Use of Proceeds: The funds will primarily be used for advancing the product pipeline, including clinical trials, regulatory submissions, and expanding the company's intellectual property portfolio, with a focus on addressing significant unmet medical needs.

Public Offering Details: Eupraxia Pharmaceuticals has priced its public offering of 12.7 million common shares at $5.50 each, aiming for gross proceeds of approximately $70 million.

Use of Proceeds: The net proceeds from the offering will be utilized for advancing the company's product pipeline, including ongoing preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up activities.